Australia’s Wegovy market is anticipated to grow at a CAGR of 16.5% through 2030, driven by high obesity rates and increasing government focus on preventive healthcare. The country’s strong regulatory environment and rising acceptance of GLP-1 therapies support adoption. However, high drug costs and reimbursement limitations under the PBS (Pharmaceutical Benefits Scheme) remain key restraints. Trends include integration of weight management drugs with digital wellness apps and primary care strategies. Opportunities exist in public-private collaborations to improve access and in expanding obesity care models within indigenous and rural populations, where healthcare disparities are more pronounced.
TABLE - Australia Wegovy Market Size & Forecast By Route of Administration 2021-2033
Route of Administration | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Injectable (Subcutaneous) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Oral (Pipeline) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Australia Wegovy Market Size & Forecast By End-User 2021-2033
End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospitals & Clinics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Retail Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Online/Telehealth Platforms | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis